INTEGRATIVE APPROACHES TO TREATING PROSTATE CANCER AND PROSTATITIS

Prostate Cancer

Patterns of Prostate Cancer Physiological vs. Pathological Maintenance vs. Cure Supplements & Adjuvant Therapy

Prostate Cancer General Guidelines

Grade of the Disease Stage of the Disease PSA Therapeutic Surgery, Radiation, Hormonal Hormonal Refractory Disease Grade & State of the Person

Prostate Cancer-Stages

Biopsy Watchful Waiting Local Therapy Hormonal Therapy Androgen Independent Advanced Disease

Prostate Cancer Evaluation

History: Risk Factors, Family History, Age, Ethnicity

Physical Exam - Digital Rectal Exam PSA - Discussion Laboratory Testing

History

Big Picture Details Flow Timing & Rhythms

Physical Exam

Traditional Temperature Distribution Excess & Deficiencies Relationships Pulse Diagnosis Tongue Diagnosis

Laboratory Testing

General Cancer Specific

Laboratory Testing - Continued

General Circulation Inflammation Hormonal Metabolic Immune Cancer Markers

Circulation & Inflammation

LP(a) CRP Fibrinogen Galectin-3 Homocysteine PT/PTT IL-8, IL-6

Cancer Markers

The more you test, the better

Laboratory Testing Prostate Cancer

CBC Comp Metabolic Panel Lipid Panel Lipo (a) PSA Free/Total PCA-3 PAP Fibrinogen Testosterone Free/Total Dihydrotestosterone (DHT) Estrone Sulfate Estradiol Total Estrogens Progesterone

Prolactin Thyroid - TSH, Others HbA1-C IGF-1 Fasting insulin C-reactive protein (CRP) Homocysteine Urine Deoxypyridinoline (DpD) Urine Pyridinium Crosslinks Carcinoembryonic Antigen (CEA) Luteinizing hormone (LH) Galectin-3 Other testing:

24 hour urine hormone evaluation with estrogen metabolites

Heavy metal urine challenge test

Immune

CBC with Differential IL-2 IL-6 IL-8 NK Cells

Metabolic

IGF-1 Insulin HbA1C Cortisol Thyroid Panel Urine DpD Melatonin Others

Imaging: General & Cancer Specific

MRI MRI-S PET vs CT Color Doppler Ultrasound Prostascint Scan Bone Scan

Approaches & Strategies

Prevention of Metastasis & Angiogenesis Immune Enhancement Hormonal & Metabolic Modulation Direct Cytotoxicity Antioxidants, Anti Inflammatory & Anti Microbial Detoxification Circulation & Hyper Viscosity Improvement Redifferentiation

PREVENTION OF METASTASIS AND ANGIOGENESIS WITHMODIFIED CITRUS PECTIN

MODIFIED CITRUS PECTINPROSTATE CANCER RESEARCH

Published Clinical and Preclinical Data

Inhibition of Spontaneous Metastasis in a Rat Prostate Model by Oral Administration of Modified Citrus Pectin

Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle, TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A Wayne State University School of Medicine, Detroit, MI, USAJ Natl Cancer Inst 1995 87(5):348-53.

Method: MCP’s inhibition of prostate cell adhesion to endothelial cells.

0.1% and 1.0% MCP in rats’ drinking water; controls had plain water

Results: Significant reduction in lung metastases -- 50% reduction in 0.1% group; 56% reduction in 1.0% group (P<0.03 & P<0.001).

Conclusion: MCP acted as potent inhibitor of spontaneous prostate carcinoma metastasis.

No Response Stable Disease Response0%

10%

20%

30%

40%

50%

60%

70%

80%

14% 14%

71%

% In

cre

as

e in

PS

AD

TEffect of Modified Citrus Pectin on PSA Doubling Time in Prostate Cancer Patients: A Pilot Clinical Trial

Method: MCP 15 g/day to patients with biochemical relapse post local therapy. PSA Doubling Time (PSADT) evaluated at intervals.

Results: MCP significantly increased PSADT in prostate cancer patients.

Strum S, Scholz M, McDermed J, McCulloch M, Eliaz, IProstate Oncology Specialist, Marina del Rey, CA, USAAmitabha Medical Clinic & Healing Center, Sebastopol, CA, USAEcoNugenics, Santa Rosa, CA, USA. International Conference on Diet & The Prevention of Cancer 1999, Tampere, Finland.

Patient MCP Use (Months)

PSADT Change Status

Patient 1 5 193% Response

Patient 2 6 193% Response

Patient 3 3 80% Response

Patient 4 >15 55% Response

Patient 5 6 6% P. Response

Patient 6 6 -7% Stable Disease

Patient 7 5 -69% No Response

Pilot Clinical Results: MCP’s Effect on PSA Doubling Time

Modified Citrus Pectin Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study

Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI Healing Touch Oncology, Marina del Rey, CA, USA Prostate Cancer & Prostatic Disease 2003;6(4):301-4.

Method: 10 men with biochemical prostate cancer relapse used MCP: 15g daily for 1 year.

Results: MCP significantly increased PSADT in 7 out of the 10 participants (p<0.01).

Patie

nt-1

Patie

nt-2

Patie

nt-3

Patie

nt-4

Patie

nt-5

Patie

nt-6

Patie

nt-7

Patie

nt-8

Patie

nt-9

Patie

nt-1

0

0%

50%

100%

150%

200%

250%

300%

350%

400%

450%

500% Post-MCP Pre-MCP

PSA

DT

as %

of P

re M

CP

*

*

*

*

* P<0.01*

968 %

*

*

Phase II Study: PSADT Results After 1 Year

Using Splines to Detect Changes in PSA Doubling TimesGuess B, Jennrich R, Johnson H, Redheffer R, Scholz M, Healing Touch Oncology, Marin del Ray, CA, Department of Statistics, UCLA, CA, The Prostate 2003 54:88-95.

MCP

Typical Patient Results

Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin

Azémar M, Hildenbrand B, Haering B, Heim ME, Unger C, Albert-Ludwigs-University in Freiburg, Germany, Sonnenberg-Klinik, Bad Sooden-Allendorf, Germany

Method: MCP 15g daily. Results: 49 patients with advanced solid tumors. 29

evaluated after 2 months -- 21% showed stabilization & improvements in quality of life. One patient w/ metastasized prostate carcinoma showed 50%

decrease in PSA, with significant increase in quality of life & decrease in pain.

Conclusion: MCP shows clinical benefits & improvements in quality of life in advanced cancer patients.

IMMUNE ENHANCEMENT IN PROSTATE CANCER TREATMENT

Immune Enhancement

Medicinal Mushrooms Modified Citrus Pectin Honokiol Botanicals - Astragalus, Eleutherococcus, Others BCG (Bacillus Calmette-Guérin) Vaccine

DIRECT CYTOTOXICITY

Direct Cytotoxicity in Prostate Cancer Treatment

Curcumin, Green Tea Extracts

Ban Zhi Lian (Scutellariae barbata)

Artemisinin

MCP

Honokiol

MCP + Honokiol

Others

24 hours 48 hours 72 hours

Pro

lifer

atio

n In

dex

(%

)

0

20

40

60

80

100

120 0 5 10 20 40 *

*

*

*

*

*

*

*

Effect of Honokiol on Growth of PC3 Cells (Pre-Published data)

Synergistic Effect of MCP & Honokiol on PC3 Cell Line Migration (Pre-Published Data)

0102030405060708090

100%Migration of PC3 Cells

% M

igratio

n

0

20

40

60

80

100

120

P<0.01

P<0.01

P<0.01

MCP 0 0.25 0.5 1.0 0 0.25 0.5 1.0 mg/ml

ProstaCaid 10 10 10 10 g/mlBA

Poly Botanical & MCP Effect on Migration of Human Prostate Cancer Cells

The invasive behavior of PC3 evaluated using migration assay in the presence of (A) MCP (mg/mL) & (B) MCP (mg/mL) plus Poly Botanical (10 ug/mL).

Poly Botanical

CIRCULATION ANDHYPERVISCOSITY IMPROVEMENT IN PROSTATE CANCER TREATMENT

Medications, Supplements & Approaches

Aspirin Clopidogrel LMW Heparin Nattokinase Lumbrokinase Botanicals Exercise

Redifferentiation

Vitamin D3 Sodium Phenyl Butyrate (SPB) Honokiol